Home » News » Recent News

Recent News

Altium Affirmed as One of Australia’s Greatest Ever Technology Companies on $9b Takeover

February 20th, 2024

Altium Ltd has origins in Hobart in the 1980’s, and sells software to help people design printed circuit boards. Following an IPO, the stock at one stage reached a low of $0.08, however, in testament to the company’s success, the company has entered a scheme of implementation agreement in February 2024 for Japan’s Renesas Electronics to acquire the company at $68.50 a share (equating to an enterprise value of around $9bn). Throughout a surge in the shareprice of tech stocks […]

Read More

ATO Release New Information around Public Disclosure of R&D Claims

January 29th, 2024

The Australian Taxation Office (ATO) has in recent months published information around publication of Research and Development (R&D) expenditure claimant information. An additional update was provided by the ATO in late January 2024 which notes: The annual Research and Development tax transparency reporting will publish information about R&D claims; Each year, the ATO will publish: the required information on data.gov.au; the ATO’s contextual analysis – the R&D tax transparency report – on the ATO website. The information the ATO will publish […]

Read More

December 2023 MYEFO indicates cost of R&D Tax Incentive is growing

January 9th, 2024

The 2023‑24 Mid‑Year Economic and Fiscal Outlook (MYEFO) was released by the Government in December 2023. New estimates within MYEFO show the R&D Tax Incentive (‘RDTI’) is expected to cost an extra $2.1 billion over the next four years, including an additional $432 million in FY22-23. According to the report, the increase is being driven primarily by claims arising from biomedicine, artificial intelligence, and machine learning activities. It’s part of a growing trend: software claims accounted for 30% of RDTI […]

Read More

Significant Refundable R&D Offsets Receipts Reported to the ASX in Recent Months

December 13th, 2023

Over recent months, a number of companies have reported to the ASX receipt of substantial Refundable R&D Tax Offsets. Notable receipts include: Syntara Limited (ASX: SNT) reported a $5.25 million Refundable R&D tax offset related to its clinical development pipeline including PXS-5505 in myelofibrosis project; Neurotech International (ASX: NTI) reported a $3.17 million Refundable R&D tax offset related to its development of treatments for paediatric neurological disorders ClearVue Technologies Limited (ASX:CPV) reported a $0.94 million Refundable R&D tax offset related […]

Read More

Categories

Archives